Cargando…

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiggens, Emily, Mortoglou, Maria, Grant, Guy H., Uysal-Onganer, Pinar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620733/
https://www.ncbi.nlm.nih.gov/pubmed/34828525
http://dx.doi.org/10.3390/healthcare9111478
_version_ 1784605290574905344
author Jiggens, Emily
Mortoglou, Maria
Grant, Guy H.
Uysal-Onganer, Pinar
author_facet Jiggens, Emily
Mortoglou, Maria
Grant, Guy H.
Uysal-Onganer, Pinar
author_sort Jiggens, Emily
collection PubMed
description Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches.
format Online
Article
Text
id pubmed-8620733
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86207332021-11-27 The Role of CDK4 in the Pathogenesis of Pancreatic Cancer Jiggens, Emily Mortoglou, Maria Grant, Guy H. Uysal-Onganer, Pinar Healthcare (Basel) Article Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches. MDPI 2021-10-30 /pmc/articles/PMC8620733/ /pubmed/34828525 http://dx.doi.org/10.3390/healthcare9111478 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jiggens, Emily
Mortoglou, Maria
Grant, Guy H.
Uysal-Onganer, Pinar
The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_full The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_fullStr The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_full_unstemmed The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_short The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_sort role of cdk4 in the pathogenesis of pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620733/
https://www.ncbi.nlm.nih.gov/pubmed/34828525
http://dx.doi.org/10.3390/healthcare9111478
work_keys_str_mv AT jiggensemily theroleofcdk4inthepathogenesisofpancreaticcancer
AT mortogloumaria theroleofcdk4inthepathogenesisofpancreaticcancer
AT grantguyh theroleofcdk4inthepathogenesisofpancreaticcancer
AT uysalonganerpinar theroleofcdk4inthepathogenesisofpancreaticcancer
AT jiggensemily roleofcdk4inthepathogenesisofpancreaticcancer
AT mortogloumaria roleofcdk4inthepathogenesisofpancreaticcancer
AT grantguyh roleofcdk4inthepathogenesisofpancreaticcancer
AT uysalonganerpinar roleofcdk4inthepathogenesisofpancreaticcancer